About US
Contact us
-
Eli Lilly and Adocia to co-develop ultra-rapid insulinEli Lilly and Company has entered a worldwide licensing collaboration with France-based Adocia to develop an ultra-rapid insulin, BioChaperone Lispro, to treat people with type 1 and type 2 diabetes.2014/12/25
-
Higher doses of vancomycin linked to increased risk of kidney damage in children, shows studyResults of a small Johns Hopkins Children’s Center study show that hospitalized children given high-dose IV infusions of the antibiotic vancomycin to treat drug-resistant bacterial infections face an2014/12/25
-
GSK submits sNDA for additional indication of eltrombopag to treat ITPGlaxoSmithKline (GSK) has submitted a supplemental new drug application (sNDA) to US Food and Drug Administration (FDA) for eltrombopag (Promacta). GSK are seeking additional approval to treat paedia2014/12/24
-
Merck acquires Swiss oncology drug development company OncoEthixUS-based drugmaker Merck has acquired Swiss biotechnology company specialised in oncology drug development, OncoEthix. Merck acquired the company through a subsidiary. OncoEthix will receive an upfr2014/12/24
-
AstraZeneca’s Lynparza obtains European approval for BRCA-mutated ovarian cancerBritish-Swedish drugmaker AstraZeneca has obtained approval from the European Commission (EC) for its twice-daily Lynparza (olaparib) capsules (400mg). Lynparza capsules can be first therapy to treat2014/12/23
-
Lilly, Adocia team up to develop BioChaperone Lispro insulin for treatment of diabetesEli Lilly and Company (NYSE: LLY) and Adocia (Euronext Paris: FR0011184241 – ADOC) today announced a worldwide licensing collaboration focused on developing an ultra-rapid insulin, known as BioChapero2014/12/23
-
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infectionThe U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) VIEKIRA PAK™, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patient2014/12/22
-
NICE recommends Boehringer Ingelheim's Pradaxa to treat fatal blood clots in adultsThe UK's National Institute for Health and Care Excellence (NICE) has recommended the anti-blood clotting drug dabigatran, Boehringer Ingelheim's Pradaxa, to treat fatal blood clots in the legs (deep2014/12/22
-
Pharma Technology Focus - Issue 33The rate of M&A activity in the pharma industry is showing no signs of slowing down, but will the resulting lack of healthy competition lead to a decline in research and innovation? We investigate2014/12/22
-
GSK forms new European consortium to advance Ebola vaccine candidateGlaxoSmithKline (GSK) and three leading research institutions have formed a new European consortium to help further advance development of a candidate vaccine against Ebola. The Ebola vaccine candida2014/12/19